PRELIMINARY REPORT ON PHENOXYPROPAZINE
Abstract
A preliminary clinical investigation of a new MAO inhibiting antidepressant, phenoxypropazine, is reported. Of 20 cases, 14 were improved, and in 12 cases the response was highly satisfactory after 6 weeks. Side effects were comparatively few, and with one exception, mild. Hypotensive activity was slight.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).